MOESM6 of Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets

  • Jian-Ying Chuang (Creator)
  • Shang Hung Chen (Contributor)
  • Ka Yen Yang (Creator)
  • Chia Hung Chien (Contributor)
  • Jr Jiun Liu (Creator)
  • Tsung-I Hsu (Contributor)
  • Kwang Yu Chang (Contributor)
  • Shun Tai Yang (Creator)
  • Jui Mei Chu (Contributor)
  • Shao Wen Chou (Creator)
  • Wei-Lun Lo (Creator)
  • Ming Sheng Liu (Creator)
  • Chih Yuan Huang (Contributor)
  • Wen-Bin Yang (Creator)
  • Pin Yuan Chen (Contributor)
  • Pei Hsuan Chung (Contributor)



Additional file 6: Figure S6. DETC inhibitor used in vitro and in vivo. (A) (Left) U87MG spheres were treated with different doses of DETC as indicated. The cell lysates were analyzed via western blot. The statistic results (Right) were shown. (B) Mice that received U87MG-r#10 cells were randomly treated with TMZ or TMZ/DETC for 5 consecutive days. Representative images of IHC staining in which the specific protein levels of the resistant xenografts were analyzed. *Pâ
Date made available2019

Cite this